Home Conference Coverage

Conference Coverage

In vivo data Shows Efficacy of Synaffix’ Proprietary Exatecan Linker-Payload to be on par...

In a poster presented during the virtual World ADC meeting, being held September 15 - 17, 2020 scientists at...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2020: Late-Breaking Data for HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC

Data for patritumab deruxtecan (U3-1402; Daiichi Sankyo) and fam-trastuzumab deruxtecan-nxki* (Enhertu®; Daiichi Sankyo/AstraZeneca), two antibody-drug conjugates (ADC) based on...
Photo: Exhibition - Bird's Eye Overview. The 15th annual PEGS: The Essential Protein Engineering Summit brought more than 2,700 world-renowned experts, visionaries, and influencers from top pharma, biotech, academic, and government institutions to the Seaport World Trade Center in Boston, MA this past April 8-12, 2019, setting record-breaking attendance. Photo courtesy: CHI/PEGS

PEGS: Novel Technology to Enhance Cell Line Productivity and Expand the Antibody-Drug Conjugate Therapeutic...

During the 16th Annual PEGS Boston Virtual Conference & Expo, which took place between August 31 – September 4,...

Preclinical Data from Magenta’s CD45-ADC Demonstrates Successful Immune Reset to Halt Disease Progression

Data presented during the 46th annual (virtual) meeting of the European Society for Blood and Marrow Transplantation (EBMT), held...

Preclinical Data Suggests Synergy between STRO-002 and Immune Checkpoint Inhibitors, Resulting in Tumor Regression...

Data presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020...
Photo: Before the pandemic - the annual meeting of the AACR/American Association for Cancer Research: Photo courtesy: 2015 AACR/Todd Buchanan.

AACR 2020: SBT6050 Demonstrates Potent Activation of Human Myeloid Cells and the Potential for...

Preclinical data for the ImmunoTAC™ candidate SBT6050, being developed by Silverback Therapeutics, presented during the American Association for Cancer...

AACR 2020: A Next Generation of FRα-Targeting ADC Engineered to Maximize Potential Clinical Benefit...

Preclinical data for ImmunoGen's next-generation anti-folate receptor alpha (FRα) ADC, IMGN151, which is being investigated in tumors with a...

Disitamab Vedotin Shows Clinically Meaningful Response and Survival Benefit in Heavily Pretreated Advanced Gastric...

Data from a phase II study of disitamab vedotin (previously known as RC48) shows clinically meaningful results in the...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial

Maturing data from the pivotal Phase II LOTIS 2 study (NCT04384484), a clinical trial of loncastuximab tesirine (formerly ADCT-402)...
Photo: Photo ASCO meeting. Photo Courtesy: ASCO/Todd Buchanan 2015

ASCO 2020 – Promising Development in the Advancement of Antibody-drug Conjugates

With an increasing number of antibody-drug conjugates (ADC) being approved and commercially available for the treatment of patients with...